These findings provide additional evidence in support of the effect of these hormones on AT and a rationale for the potential mechanisms by which GLP-1/GIP and GLP-1/glucagon dual agonist drugs can achieve metabolic benefits in patients with obesity and T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.